An immunotherapy advance pioneered at Memorial Sloan Kettering continues to demonstrate remarkable results. Researchers reported in Science Translational Medicine that 88 percent of advanced leukemia patients achieved complete remissions after being treated with genetically modified versions of their own immune cells.
The new treatment, known as targeted immunotherapy, harnesses the power of the body’s own immune system to fight cancer. Patients’ own immune cells, called T cells, are removed and genetically altered to recognize and attack a protein found on cancer cells. They are then infused back into the patient, where they multiply and attack.
Study authors Renier Brentjens and Michel Sadelain are available to discuss the current research findings and the implications for future study. Patients who have received novel immune therapies are also available for interviews.
New Trial Advances Cell-Based Immune Therapy for Certain Leukemias
Cell Therapy Shows Remarkable Ability to Eradicate Cancer in Clinical Study
For more information and to set up an interview, contact the Media Staff.